Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3202620 | 0.88 | SRC (0.43) | MMEACE2CYP2D6SRCLMNA | |
| SCHEMBL3215199 | 0.88 | SRC (0.43) | MMEACE2CYP2D6SRCLMNA | |
| SCHEMBL3215149 | 0.82 | RIPK1 (0.41) | MMEACE2CYP2D6SRCLMNA | |
| SCHEMBL1171448 | 0.81 | GABBR2 (0.39) | MAPK1HIF1ASMN1; SMN2CYP2C19 | |
| SCHEMBL3209374 | 0.80 | NAALAD2 (0.37) | CYP2D6MAPK1HIF1ACYP1A2CYP2C19 | |
| SCHEMBL3215191 | 0.79 | MAPK1 (0.47) | MMEACE2CYP2D6SRCLMNA | |
| Ethylene Glycol SCHEMBL3208351 | 0.79 | SRC (0.48) | MMEACE2CYP2D6SRCLMNA | |
| Ethylene Glycol SCHEMBL5345328 | 0.79 | SRC (0.48) | MMEACE2CYP2D6SRCLMNA | |
| SCHEMBL74366 | 0.78 | SRC (0.56) | MMEACE2CYP2D6SRCLMNA | |
| Di(Hydroxyethyl)Ether SCHEMBL3212524 | 0.78 | CYP2D6 (0.41) | MMEACE2CYP2D6SRCLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029876-A1 | POLYMERIZATION ACCELERATOR, CURABLE COMPOSITION, CURED PRODUCT, AND PROCESS FOR PRODUCING THIOL COMPOUND | SHOWA DENKO K.K. (JP) | 2010-02-04 | — | — | US | disclosed |
| EP-2030989-A1 | POLYMERIZATION ACCELERATOR, CURABLE COMPOSITION, CURED PRODUCT AND METHOD FOR PRODUCING THIOL COMPOUND | Showa Denko K.K. (JP) | 2009-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029876-A1 | POLYMERIZATION ACCELERATOR, CURABLE COMPOSITION, CURED PRODUCT, AND PROCESS FOR PRODUCING THIOL COMPOUND | TMT1A, CCNT1, MGMT | MME 4385/4885ACE2 3735/4885CYP2D6 4344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.